LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article: Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis

    Kato, Kosuke / Papageorgiou, Ioannis / Shin, Yoon-Joo / Kleinhenz, Jennifer M. / Palumbo, Sunny / Hahn, Seongmin / Irish, Joseph D. / Rounseville, Skye P. / Knox, Kenneth S. / Hecker, Louise

    Antioxidants. 2022 Feb. 28, v. 11, no. 3

    2022  

    Abstract: Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated antioxidant responses. Tecfidera is an orally administered FDA-approved drug for the treatment of multiple sclerosis, where the active pharmaceutical ingredient is dimethyl fumarate (DMF), an active Nrf2 activator. However, no studies have evaluated the efficacy of DMF for age-associated persistent lung fibrosis. Here, we demonstrate that in IPF lung fibroblasts, DMF treatment inhibited both TGF-β-mediated pro-fibrotic phenotypes and led to a reversal of established pro-fibrotic phenotypes. We also evaluated the pre-clinical efficacy of lung-targeted (inhaled) vs. systemic (oral) delivery of DMF in an aging murine model of bleomycin-induced persistent lung fibrosis. DMF or vehicle was administered daily to aged mice by oral gavage or intranasal delivery from 3–6 weeks post-injury when mice exhibited non-resolving lung fibrosis. In contrast to systemic (oral) delivery, only lung-targeted (inhaled) delivery of DMF restored lung Nrf2 expression levels, reduced lung oxidative stress, and promoted the resolution of age-dependent established fibrosis. This is the first study to demonstrate the efficacy of lung-targeted DMF delivery to promote the resolution of age-dependent established lung fibrosis.
    Keywords active pharmaceutical ingredients ; animal models ; antioxidants ; dimethyl fumarate ; drugs ; fibroblasts ; fibrosis ; lungs ; oxidative stress ; pulmonary fibrosis ; sclerosis
    Language English
    Dates of publication 2022-0228
    Publishing place Multidisciplinary Digital Publishing Institute
    Document type Article
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox11030492
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article: Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis.

    Kato, Kosuke / Papageorgiou, Ioannis / Shin, Yoon-Joo / Kleinhenz, Jennifer M / Palumbo, Sunny / Hahn, Seongmin / Irish, Joseph D / Rounseville, Skye P / Knox, Kenneth S / Hecker, Louise

    Antioxidants (Basel, Switzerland)

    2022  Volume 11, Issue 3

    Abstract: Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF), a severe and deadly form of lung fibrosis, is widely regarded as a disease of aging. We previously demonstrated that aged mice with persistent lung fibrosis and IPF lung myofibroblasts exhibit deficient Nrf2-mediated antioxidant responses. Tecfidera is an orally administered FDA-approved drug for the treatment of multiple sclerosis, where the active pharmaceutical ingredient is dimethyl fumarate (DMF), an active Nrf2 activator. However, no studies have evaluated the efficacy of DMF for age-associated persistent lung fibrosis. Here, we demonstrate that in IPF lung fibroblasts, DMF treatment inhibited both TGF-β-mediated pro-fibrotic phenotypes and led to a reversal of established pro-fibrotic phenotypes. We also evaluated the pre-clinical efficacy of lung-targeted (inhaled) vs. systemic (oral) delivery of DMF in an aging murine model of bleomycin-induced persistent lung fibrosis. DMF or vehicle was administered daily to aged mice by oral gavage or intranasal delivery from 3-6 weeks post-injury when mice exhibited non-resolving lung fibrosis. In contrast to systemic (oral) delivery, only lung-targeted (inhaled) delivery of DMF restored lung Nrf2 expression levels, reduced lung oxidative stress, and promoted the resolution of age-dependent established fibrosis. This is the first study to demonstrate the efficacy of lung-targeted DMF delivery to promote the resolution of age-dependent established lung fibrosis.
    Language English
    Publishing date 2022-02-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox11030492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing.

    Kato, Kosuke / Shin, Yoon-Joo / Palumbo, Sunny / Papageorgiou, Ioannis / Hahn, Seongmin / Irish, Joseph D / Rounseville, Skye P / Krafty, Robert T / Wollin, Lutz / Sauler, Maor / Hecker, Louise

    The European respiratory journal

    2021  Volume 58, Issue 5

    MeSH term(s) Aging ; Humans ; Idiopathic Pulmonary Fibrosis/drug therapy ; Indoles/therapeutic use ; Protein Kinase Inhibitors
    Chemical Substances Indoles ; Protein Kinase Inhibitors ; nintedanib (G6HRD2P839)
    Language English
    Publishing date 2021-11-25
    Publishing country England
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00759-2021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging.

    Kato, Kosuke / Logsdon, Naomi J / Shin, Yoon-Joo / Palumbo, Sunny / Knox, Adam / Irish, Joseph D / Rounseville, Skye P / Rummel, Sydney R / Mohamed, Mohamed / Ahmad, Kareem / Trinh, Johnny M / Kurundkar, Deepali / Knox, Kenneth S / Thannickal, Victor J / Hecker, Louise

    American journal of respiratory cell and molecular biology

    2020  Volume 62, Issue 5, Page(s) 633–644

    Abstract: Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease with no cure. Although IPF is widely regarded as a disease of aging, the cellular mechanisms that contribute to this age-associated predilection remain elusive. In this study, we ... ...

    Abstract Idiopathic pulmonary fibrosis (IPF) is a fatal age-associated disease with no cure. Although IPF is widely regarded as a disease of aging, the cellular mechanisms that contribute to this age-associated predilection remain elusive. In this study, we sought to evaluate the consequences of senescence on myofibroblast cell fate and fibrotic responses to lung injury in the context of aging. We demonstrated that nonsenescent lung myofibroblasts maintained the capacity for dedifferentiation, whereas senescent/IPF myofibroblasts exhibited an impaired capacity for dedifferentiation. We previously demonstrated that the transcription factor MyoD acts as a critical switch in the differentiation and dedifferentiation of myofibroblasts. Here, we demonstrate that decreased levels of MyoD preceded myofibroblast dedifferentiation and apoptosis susceptibility in nonsenescent cells, whereas MyoD expression remained elevated in senescent/IPF myofibroblasts, which failed to undergo dedifferentiation and demonstrated resistance to apoptosis. Genetic strategies to silence MyoD restored the susceptibility of IPF myofibroblasts to undergo apoptosis and led to a partial reversal of age-associated persistent fibrosis
    MeSH term(s) Aged ; Aging/pathology ; Animals ; Apoptosis ; Cell Differentiation ; Cell Line ; Cellular Senescence ; Female ; Fibrosis ; Gene Knockdown Techniques ; Humans ; Idiopathic Pulmonary Fibrosis/pathology ; Mice, Inbred C57BL ; Middle Aged ; Molecular Targeted Therapy ; MyoD Protein/metabolism ; Myofibroblasts/pathology ; Up-Regulation
    Chemical Substances MyoD Protein
    Language English
    Publishing date 2020-01-20
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1025960-0
    ISSN 1535-4989 ; 1044-1549
    ISSN (online) 1535-4989
    ISSN 1044-1549
    DOI 10.1165/rcmb.2019-0092OC
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top